Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

This phase I–II study explored safety, immunomodulatory and clinical effects of lenalidomide (weeks 1–16) and alemtuzumab (weeks 5–16) in 23 patients with refractory chronic lymphocytic leukemia. Most patients had Rai stage III/IV disease and were heavily pretreated (median 4 prior therapies), and 6...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Immunol Immunother
Hlavní autoři: Winqvist, Maria, Mozaffari, Fariba, Palma, Marzia, Eketorp Sylvan, Sandra, Hansson, Lotta, Mellstedt, Håkan, Österborg, Anders, Lundin, Jeanette
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2016
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5222940/
https://ncbi.nlm.nih.gov/pubmed/27815572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1922-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky